Indications, feasibility, safety, and efficacy of CyberKnife radiotherapy for the treatment of olfactory groove meningiomas: a single institutional retrospective series

Autor: Ekkehard M. Kasper, Farhan A Mirza, Rafael Rojas, Anand Mahadevan, Fred C. Lam, Jianmin Liu
Jazyk: angličtina
Rok vydání: 2020
Předmět:
lcsh:Medical physics. Medical radiology. Nuclear medicine
Male
medicine.medical_specialty
Olfactory groove meningiomas
lcsh:R895-920
medicine.medical_treatment
Radiosurgery
lcsh:RC254-282
Resection
Stereotactic radiotherapy
03 medical and health sciences
0302 clinical medicine
Cyberknife
Olfactory Groove Meningioma
medicine
Meningeal Neoplasms
Humans
Radiology
Nuclear Medicine and imaging
Stereotactic radiosurgery
Aged
Retrospective Studies
Aged
80 and over
Fractionated stereotactic radiotherapy
Hypofractionated stereotactic radiotherapy
business.industry
Research
Rate control
CyberKnife radiotherapy
Radiotherapy Dosage
Middle Aged
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Prognosis
Radiation therapy
Survival Rate
Oncology
030220 oncology & carcinogenesis
Feasibility Studies
Female
Radiation Dose Hypofractionation
Radiology
Radiotherapy
Intensity-Modulated
Post treatment
business
Meningioma
030217 neurology & neurosurgery
Zdroj: Radiation Oncology (London, England)
Radiation Oncology, Vol 15, Iss 1, Pp 1-10 (2020)
ISSN: 1748-717X
Popis: Purpose To assess the safety and efficacy of CyberKnife® radiotherapy (CKRT) for the treatment of olfactory groove meningiomas (OGMs). Methods A retrospective review was performed of 13 patients with OGM treated with CKRT from September 2005 to May 2018 at our institution. Nine patients were treated primarily with CKRT, 3 for residual disease following resection, and 1 for disease recurrence. Results Five patients were treated with stereotactic radiosurgery (SRS), 6 with hypofractionated stereotactic radiotherapy (HSRT), and 2 with fractionated stereotactic radiotherapy (FSRT). The median tumor volume was 8.12 cm3. The median prescribed dose was 14.8 Gy for SRS, 27.3 Gy for HSRT, and 50.2 Gy for FSRT. The median maximal dose delivered was 32.27 Gy. Median post treatment follow-up was 48 months. Twelve of 13 patients yielded a 100% regional control rate with a median tumor volume reduction of 31.7%. Six of the 12 patients had reduced tumor volumes while the other 6 had no changes. The thirteenth patient had significant radiation-induced edema requiring surgical decompression. Twelve patients were alive and neurologically stable at the time of the review. One patient died from pneumonia unrelated to his CKRT treatment. Conclusions CKRT appears to be safe and effective for the treatment of OGMs.
Databáze: OpenAIRE
Externí odkaz: